Korro Bio Inc. is an RNA editing company focused on the discovery and development of a new class of precision genetic medicines for both rare and highly prevalent diseases. Korro Bio Inc., formerly known as Frequency Therapeutics Inc., is based in LEXINGTON, Mass.
| Revenue (Most Recent Fiscal Year) | $2.27M |
| Net Income (Most Recent Fiscal Year) | $-83.58M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.70 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.65 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1198.11% |
| Net Margin (Trailing 12 Months) | -1199.53% |
| Return on Equity (Trailing 12 Months) | -68.87% |
| Return on Assets (Trailing 12 Months) | -45.91% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.71 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.71 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $17.12 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.92 |
| Earnings per Share (Most Recent Fiscal Year) | $-9.37 |
| Diluted Earnings per Share (Trailing 12 Months) | $-9.41 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 9.42M |
| Free Float | 8.98M |
| Market Capitalization | $64.13M |
| Average Volume (Last 20 Days) | 1.11M |
| Beta (Past 60 Months) | 3.03 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 13.18% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |